Trials / Completed
CompletedNCT00792298
Phase IIB 2-Period Crossover Polysomnography Study in Participants With Primary Insomnia (MK-4305-006)
A Phase IIb, Multicenter, Randomized, Double-Blind Placebo-Controlled, 2-period Adaptive Crossover Polysomnography Study to Evaluate Safety and Efficacy of MK-4305 in Patients With Primary Insomnia
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 254 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years – 64 Years
- Healthy volunteers
- Not accepted
Summary
A cross-over, polysomnography study to test the safety, tolerability and effectiveness of different doses of suvorexant (MK-4305) in the treatment of patients with primary insomnia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Suvorexant | oral tablet taken before bedtime |
| DRUG | Dose-matched Placebo to Suvorexant | Dose-matched placebo to suvorexant taken before bedtime (oral tablet) |
Timeline
- Start date
- 2008-11-05
- Primary completion
- 2009-12-26
- Completion
- 2009-12-26
- First posted
- 2008-11-17
- Last updated
- 2018-11-06
- Results posted
- 2014-11-14
Source: ClinicalTrials.gov record NCT00792298. Inclusion in this directory is not an endorsement.